View our 2020 Corporate Responsibility Report
Read more about how we continued to operate as a responsible business, supported our communities and drove lasting social and environmental change in 2020.
Australian regulatory authority, the TGA, approves our fourth cystic fibrosis medicine for eligible people with CF
See what this announcement means for patients in Australia and how it speaks to Vertex's ultimate goal of developing and providing treatments for people with CF around the world.
Type 1 Diabetes Cell Therapy IND Receives FDA Clearance
Vertex announced the clearance of our Investigational New Drug (IND) Application for our type 1 diabetes cell therapy, enabling a clinical trial to begin.
Vertex Receives Priority Review by Health Canada for a New Drug Submission for the Treatment of Cystic Fibrosis
COVID-19 Information and Resources
Keeping you informed as the COVID-19 pandemic evolves